Mondesert, E, Delaby, C, de la Cruz, E, Kuhle, J, Benkert, P, Pradeilles, N, Duchiron, M, Morchikh, M, Camu, W, Cristol, JP, Hirtz, C, Esselin, F, Lehmann, S. Comparative Performances of 4 Serum NfL Assays, pTau181, and GFAP in Patients With Amyotrophic Lateral Sclerosis. NEUROLOGY. 2025; 104(6)DOI:10.1212/WNL.0000000000213400. PMID:40009787. IF:8.500(Q1/1D).

Lleó, A. New treatments in Alzheimer's disease. MEDICINA CLINICA. 2025; 164(5)DOI:10.1016/j.medcli.2024.10.011. PMID:39616028. IF:2.100(Q2/3D).

Xu, XY, Kwon, J, Yan, RQ, Apio, C, Song, SM, Heo, G, Yang, QJ, Timsina, J, Liu, MH, Budde, J, Blennow, K, Zetterberg, H, Lleo, A, Ruiz, A, Molinuevo, JL, Lee, VMY, Deming, Y, Heslegrave, AJ, Hohman, TJ, Pastor, P, Peskind, ER, Albert, MS, Morris, JC, Park, T, Cruchaga, C, Sung, YJ. Sex Differences in Apolipoprotein E and Alzheimer Disease Pathology Across Ancestries. JAMA Network Open. 2025; 8(3)DOI:10.1001/jamanetworkopen.2025.0562. PMID:40067298. IF:9.700(Q1/1D).

Soriano, LD, Wagemann, O, Bejanin, A, Levin, J, Fortea, J. Sex-related differences in genetically determined Alzheimer's disease. Frontiers in Aging Neuroscience. 2025; 17DOI:10.3389/fnagi.2025.1522434. PMID:40103931. IF:4.500(Q1/2D).

Naranjo, L, Sarto, J, Nos, C, Alcolea, D, Rodríguez-Baz, I, Navalpotro-Gómez, I, Fernández-Lebrero, A, Bertrán-Recasens, B, Erro, ME, Pelayo-Negro, AL, Esteve, C, Fernández, S, Massot-Tarrús, A, Boltes, A, Torrents, A, Guanyabens, N, Palomino-García, A, Egri, N, Lladó, A, Balasa, M, Romera, MA, Antón, MD, Couso, RS, Sánchez-Valle, R, Ruiz-García, R. Isolated CSF RT-QuIC positivity associates with a less aggressive disease course and decreased levels of neuronal/glial damage biomarkers in patients with sporadic Creutzfeldt-Jakob disease. JOURNAL OF NEUROLOGY. 2025; 272(3)DOI:10.1007/s00415-024-12757-8. PMID:39932589. IF:4.600(Q1/2D).

Bolsewig, K, Willemse, EAJ, Sánchez-Juan, P, Rábano, A, Martínez, M, Doecke, JD, Bellomo, G, Vermunt, L, Alcolea, D, Halbgebauer, S, 't Veld, SI, Mattsson-Carlgren, N, Veverova, K, Fowler, CJ, Boonkamp, L, Koel-Simmelink, M, Hussainali, Z, Ruiters, DN, Gaetani, L, Toja, A, Fortea, J, Pijnenburg, Y, Lemstra, AW, van der Flier, WM, Hort, J, Otto, M, Hansson, O, Parnetti, L, Masters, CL, Lleó, A, Teunissen, CE, Milán, MD. Increased plasma DOPA decarboxylase levels in Lewy body disorders are driven by dopaminergic treatment. Nature Communications. 2025; 16(1)DOI:10.1038/s41467-025-56293-z. PMID:39881147. IF:15.700(Q1/1D).